Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Post by EternalPonzion Jan 15, 2020 9:16am
235 Views
Post# 30554772

Market Psychology/ Fear / Stupidity

Market Psychology/ Fear / Stupidity
This is very bullish. https://rivertonroll.com/news/2020/01/15/acasti-pharma-cveacst-given-news-sentiment-score-of-4-00.html No one seems to be giving the 'snippet' attached to the press release much rational analysis. https://ml.globenewswire.com/1.0/snippet/369/eng#lg=1&slide=0 For argument's sake, lets just imagine if the Placebo result as depicted in the graph had been more in-line with past studies, somewhere in the -10% - 0% range, and leave the Active results as is. What would the market reaction have likely been then? I think we can all surmise that very easily. For those of you feeling extreme buyers regret, especially if you were a Nov - early Jan buyer remember this; there was no way one could have predicted that the placebo group results would be so unusual. The only logical explanation is that an error in data analysis occurred especially as we now know in at least 5 of the sites. Selling your stake during the panic on Monday was probably an unwise decision - but many had their stop losses triggered. It is obvious that the drug clearly works and if you purchased shares in the past few months with conviction and a belief that the product is likely sound and are still mulling whether to liquidate them reflect back on your original conviction. Look at that graph again carefully, as well as the other results over the past few years. Yes, the greedy day traders and short sellers will cause a high beta for the next several trading sessions but regardless of what negative news continues to be retransmitted continue to remind yourself of the actual facts and act sensibly. Have conviction in whatever informed decision you make (goes for anything in life) and you will likely be rewarded.
<< Previous
Bullboard Posts
Next >>